CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Equities research analysts at HC Wainwright raised their FY2026 EPS estimates for CRISPR Therapeutics in a research note issued on Wednesday, August 5th. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2027 earnings at ($1.24) EPS and FY2027 earnings at ($4.98) EPS. Neutral Sentiment: Brookline Capital Markets made mixed revisions: its Q3 2026 loss estimate improved slightly to $1.30 per share from $1.31, while its FY2027 loss estimate improved to $4.51 from $5.05. Brookline Capital Markets made mixed revisions: its Q3 2026 loss estimate improved slightly to from $1.31, while its FY2027 loss estimate improved to $4.51 from $5.05. CRISPR Therapeutics Company Profile(Get Free Report)CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform.